

Financial Tear Sheet

Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$3.36
Change (%)	▼ 0.04 (1.18%)
Volume	4,516
52 Week Low	\$2.88
Market Cap	\$64,838,136
Rolling EPS	-0.26
PE Ratio	0
Shares Outstanding	19,070,040
Data as of 04/25/18 12:18 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

April 11, 2018

BRAINSTORM CELL THERAPEUTICS TO PRESENT AT ARM'S 6TH ANNUAL CELL & GENE THERAPY INVESTOR DAY, APRIL 17 IN NEW YORK

April 9, 2018

LETTER TO SHAREHOLDERS

March 28, 2018

BRAINSTORM CELL THERAPEUTICS' PHASE 3 TRIAL OF NUROWN® IN ALS NOW OPEN TO CANADIAN PATIENTS

Upcoming Events

WALL STREET INVESTOR FORUM COMPANY PRESENTATION

March 22, 2018 8:00 a.m. ET

BIO ASIA INTERNATIONAL CONFERENCE COMPANY PRESENTATION

March 19, 2018 11:45 a.m. JT

BRAINSTORM CELL THERAPEUTICS - FOURTH QUARTER AND FULL YEAR 2017 EARNINGS CALL

March 8, 2018 8:30 a.m. ET

SEC Filings

Filing Date	Form
03/26/18	4
03/26/18	4
03/20/18	4/A
03/20/18	4/A

Primary IR Contact

Michael Rice

LifeSci Advisors LLC

E-mail: mrice@lifesciadvisors.com